Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2007-05-091934PMID 17881645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

  2007cited by this paper
• Severe congenital neutropenia: inheritance and pathophysiology

  2007cited by this paper
• Neutrophil elastase in cyclic and severe congenital neutropenia.

  2007cited by this paper
• G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms.

  2007cited by this paper
• Outcome of Infants Less Than One Year of Age with Acute Lymphoblastic Leukemia Treated with the Interfant-99 Protocol.

  2006cited by this paper
• Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

  2005cited by this paper
• The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

  2005cited by this paper
• FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.

  2005cited by this paper
• Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register.

  2004cited by this paper
• Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia.

  2004cited by this paper
• Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

  2003cited by this paper
• Dysregulation of transcriptions in primary granule constituents during myeloid proliferation and differentiation in patients with severe congenital neutropenia

  2003cited by this paper
• Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2

  2003cited by this paper
• Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.

  2002cited by this paper
• Biological and therapeutic aspects of infant leukemia.

  2000cited by this paper

• How I Treat on Infant Acute Lymphoblastic Leukemia.

  2024cites this paper
• Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy

  2024cites this paper
• Prevalence of FLT3 gene mutation and its expression in Brazilian pediatric B-ALL patients: clinical implications

  2024cites this paper
• Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens

  2023cites this paper
• Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations

  2023cites this paper
• CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia

  2023cites this paper
• Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia

  2022cites this paper
• Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement

  2022cites this paper
• Neonatal Leukemia.

  2021cites this paper
• Epigenetic Control of Infant B Cell Precursor Acute Lymphoblastic Leukemia

  2021cites this paper
• FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

  2021cites this paper
• CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations

  2020cites this paper
• How I treat infant leukemia.

  2019cites this paper
• Infant ALL

  2019cites this paper
• Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody

  2019cites this paper
• Pediatric Acute Lymphoblastic Leukemia: Recent Advances for a Promising Future

  2019cites this paper
• Molecular Approaches to Treating Pediatric Leukemias

  2019influential citation
• Modern views on the treatment of acute leukemia in children under 1 year

  2019cites this paper
• Современные представления о терапии острого лейкоза у детей до 1 года

  2019cites this paper
• Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.

  2019cites this paper
• FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms.

  2019cites this paper
• Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

  2018cites this paper
• A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia

  2018cites this paper
• Next‐Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia

  2018cites this paper
• How I Treat How I treat infant leukemia

  2018cites this paper
• Targeted Therapy and Precision Medicine

  2017cites this paper
• Updates in the biology and therapy for infant acute lymphoblastic leukemia

  2017cites this paper
• MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches

  2017cites this paper
• The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia

  2017cites this paper
• Caracterització de les alteracions moleculars de FLT3 en pacients pediàtrics afectes de leucèmia aguda. Correlació amb l’activitat i expressió dels transportadors de fàrmacs derivats de nucleòsids

  2017cites this paper
• FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia

  2016cites this paper
• Two cases of in-frame deletion mutation in juxtamembrane domain of the FLT3

  2016cites this paper
• A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

  2016cites this paper
• Recent progress in the treatment of infant acute lymphoblastic leukemia

  2015cites this paper
• Childhood acute lymphoblastic leukemia: Integrating genomics into therapy

  2015cites this paper
• Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

  2015cites this paper
• Clinical value of pre‐transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease‐guided protocol

  2014cites this paper
• Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells

  2014cites this paper
• The Biology and Targeting of FLT3 in Pediatric Leukemia

  2014cites this paper
• Unraveling Glucocorticoid Resistance In MLLrearranged Infant Acute Lymphoblastic Leukemia

  2014cites this paper
• Leukemia therapy: mechanisms of drug resistance and investigational strategies.

  2014cites this paper
• FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs.

  2013cites this paper
• Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements

  2013cites this paper
• Treatment of infant leukemias: challenge and promise.

  2013cites this paper
• Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants

  2013cites this paper
• Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia

  2012cites this paper
• Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

  2012cites this paper
• Secondary mutations in t(4;11) leukemia patients

  2012cites this paper
• Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia

  2012cites this paper
• Posaconazole

  2012cites this paper
• Immunotherapy for Acute Lymphocytic Leukemia

  2011cites this paper
• FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute leukaemia—a study of 531 Southeast Asian children by the Ma‐Spore study group

  2011cites this paper
• FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia

  2011cites this paper
• Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

  2010cites this paper
• Biology and treatment of acute lymphoblastic leukemia.

  2010cites this paper
• Infant Acute Lymphoblastic Leukemia Rob Pieters

  2010cites this paper
• Chapter 22 Immunotherapy for Acute Lymphocytic Leukemia

  2010cites this paper
• Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia

  2010cites this paper
• Pharmacogenomics of pediatric acute lymphoblastic leukemia

  2010cites this paper
• Acute Leukaemia: Integration of Morphological, Immunophenotypic and Genetic Information and the WHO Classification

  2010cites this paper
• The emerging era of targeted therapy in childhood acute lymphoblastic leukemia

  2010cites this paper
• New genetic abnormalities and treatment response in acute lymphoblastic leukemia.

  2009cites this paper
• Infant acute lymphoblastic leukemia: Lessons learned and future directions

  2009cites this paper
• The molecular biology of mixed lineage leukemia

  2009cites this paper
• Biology and treatment of acute lymphoblastic leukemia.

  2008cites this paper
• The ABCs of infant leukemia.

  2008cites this paper
• nfant AML : The Highest Incidence n Infants

  2008influential citation